What is the difference between Tirzepatide and Retatrutide?

Tirzepatide is a dual GIP+GLP-1R agonist (~20-22% weight reduction). Retatrutide (LY3437943) adds GCGR (glucagon receptor) agonism, making it a triple agonist (~24-26% weight reduction). GCGR activation increases energy expenditure via thermogenesis, drives hepatic fat oxidation, and stimulates lipolysis — providing a metabolic rate increase component that dual agonists cannot. Both are available from QSC Peptides.

Tirzepatide vs Retatrutide — Dual vs Triple Agonist

// Side-by-Side

Tirzepatide vs Retatrutide — Direct Comparison

Property	Tirzepatide	Retatrutide (LY3437943)
Drug Class	Dual GIP+GLP-1R	Triple GLP-1R+GIPR+GCGR
GLP-1R	Yes	Yes
GIPR	Yes	Yes
GCGR	No	Yes — key differentiator
Avg. Weight Reduction	~20–22%	~24–26%
Energy Expenditure ↑	Moderate	Strong (GCGR → UCP1, thermogenesis)
Hepatic Fat Reduction	Yes	Very strong (GCGR β-oxidation)
Lipolysis	Moderate (GIPR)	Strong (GCGR + GIPR)
NAFLD/NASH Research	Good	Superior (GCGR)
Half-Life	~5 days	~6 days
QSC Peptides Entry Price	$210 (15mg 10-vial)	$190 (5mg 10-vial)
Max Vial Size (QSC)	30mg	60mg

// The GCGR Question

What GCGR Agonism Adds

The GCGR (glucagon receptor) is the critical differentiator between Tirzepatide and Retatrutide. Historically, glucagon was viewed as the enemy of metabolic health — it raises blood glucose. Retatrutide's design insight is that controlled GCGR agonism, in the context of simultaneous strong GLP-1R/GIPR insulinotropic signaling, can be harnessed beneficially:

Thermogenesis: GCGR in brown adipose tissue upregulates UCP1-mediated proton uncoupling, increasing heat production and basal metabolic rate — the primary mechanism behind Retatrutide's 4–6% greater weight loss vs Tirzepatide
Hepatic β-oxidation: GCGR drives liver fatty acid oxidation and ketogenesis — rapidly reducing hepatic fat accumulation (NAFLD) far more effectively than dual agonists alone
Adipocyte lipolysis: GCGR on fat cells activates HSL, complementing GIPR-mediated lipolysis for synergistic fat mobilization
Glucose balance: GCGR hepatic glucose production is counterbalanced by GLP-1R/GIPR-enhanced insulin secretion, maintaining net glucose neutrality despite glucagonergic stimulation

When to Use Tirzepatide vs Retatrutide

Use Tirzepatide when isolating the dual incretin (GIP+GLP-1) axis without glucagon receptor involvement — pure incretin biology, GIPR/GLP-1R cross-talk, or when GCGR activity would confound results.

Use Retatrutide (LY3437943) when maximum weight reduction, hepatic fat research (NAFLD/NASH), thermogenesis/energy expenditure, or full triple-receptor pharmacology is required. Also preferred for dose-escalation research given QSC Peptides' wide 5–60mg range.

// QSC Peptides Products